Drug Trial Radar · NCT06948318
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 14, 2025
Primary completion
Jul 29, 2029
Study completion Jul 29, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time. Other aims are to learn how effective treatment with mezagitamab is and how the body processes it (called pharmacokinetics or PK) over a longer time. Participants of the following previous mezagitamab studies will be invited to join this continuation study: TAK-079-3002 and TAK-079-1004. In this continuation study, participants will receive mezagitamab when certain protocol criteria are met. During the study, participants will visit their study clinic several times.
Conditions
- Immune Thrombocytopenic Purpura (ITP)
Interventions
MezagitamabDrug
Mezagitamab injection administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Up to approximately 108 weeks
- Number of Participants With TEAEs Leading to Permanent Withdrawal of MezagitamabTime frame: Up to approximately 108 weeks
Locations
118 sites in 15 countries. Site status is shown where the registry gives one.
Genesis Cancer and Blood Institute - SCRI
Hot Springs, Arkansas · Not yet recruiting
USC Norris Comprehensive Cancer Center - Keck Medicine of USC
Los Angeles, California · Not yet recruiting
University of California San Diego Center for Bleeding and Clotting Disorders
San Diego, California · Not yet recruiting
Rocky Mountain Cancer Center
Denver, Colorado · Withdrawn
Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Not yet recruiting
Emory University
Atlanta, Georgia · Not yet recruiting
Innovative Hematology, Inc.
Indianapolis, Indiana · Not yet recruiting
The University of Iowa
Iowa City, Iowa · Not yet recruiting
University Of Louisville Brown Cancer Center
Louisville, Kentucky · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
University of Massachusetts Chan Medical School
Worcester, Massachusetts · Withdrawn
MidAmerica Cancer Center
Kansas City, Missouri · Not yet recruiting
American Oncology Partners of Maryland, PA
Morristown, New Jersey · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Not yet recruiting
Montefiore Medical Center
The Bronx, New York · Not yet recruiting
Duke University Hospital
Durham, North Carolina · Not yet recruiting
East Carolina University
Greenville, North Carolina · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Not yet recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program
Philadelphia, Pennsylvania · Not yet recruiting
Lewis Katz School of Medicine at Temple University
Philadelphia, Pennsylvania · Not yet recruiting
Baylor College of Medicine
Houston, Texas · Not yet recruiting
Virginia Oncology Associates
Norfolk, Virginia · Not yet recruiting
University of Washingto
Seattle, Washington · Not yet recruiting
Versiti Wisconsin, Inc
Milwaukee, Wisconsin · Not yet recruiting
Canberra Hospital
Garran, Australian Capital Territory, Australia · Recruiting
Concord Repatriation General Hospital
Concord, New South Wales, Australia · Not yet recruiting
St George Hospital
Kogarah, New South Wales, Australia · Recruiting
University of New South Wales (UNSW) - Liverpool Hospital - Liverpool Cancer Therapy Centre
Liverpool, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Not yet recruiting
Monash University - Australian Centre for Blood Diseases (ACBD)
Melbourne, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Fiona Stanley Hospital
Murdoch, Western Australia, Australia · Recruiting
Perth Blood Institute
West Perth, Western Australia, Australia · Recruiting
Medical Center "Fama Medical"
Plovdiv, Bulgaria · Recruiting
UMHAT Sv. Ivan Rilski
Sofia, Bulgaria · Recruiting
UMHAT SofiaMed, OOD
Sofia, Bulgaria · Recruiting
University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD
Stara Zagora, Bulgaria · Not yet recruiting
Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
Sofia, Sofia-Grad, Bulgaria · Recruiting
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.